Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | IBI3003 |
Trade Name | |
Synonyms | IBI-3003|IBI 3003 |
Drug Descriptions |
IBI3003 is a T-cell engager targeting GPRC5D and TNFRSF17 (BCMA) on tumor cells and CD3 on T-cells, which potentially induces a cytotoxic T-cell response against tumor cells expressing GPRC5D and TNFRSF17 (BCMA) (NCI Drug Dictionary). |
DrugClasses | CD3 Antibody 107 TNFRSF17 Antibody 22 |
CAS Registry Number | NA |
NCIT ID | C202244 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
IBI3003 | IBI3003 | 0 | 1 |